Saad Khanani

Silicon Valley
  • 140 Scott Drive
  • Menlo Park, CA 94025
  • USA

Saad Khanani is an associate in the Silicon Valley office of Latham & Watkins where he is a member of the Corporate Department. He previously worked in the Abu Dhabi and San Francisco offices.

Mr. Khanani represents emerging companies, venture capital, and private equity firms primarily in the technology and healthcare industries. His transactions practice focuses on general corporate counseling, venture capital financings, and mergers and acquisitions. His general company representation includes advising companies regarding formation, corporate governance, and commercial transactions.

Mr. Khanani received his JD from Columbia Law School in 2008 where he was a Kent Scholar, a member of the Columbia Business Law Review and the Faculty Rules Committee. In 2002, he received his BA in Economics and Mathematics from Yale University. Prior to joining Latham, he worked at McKinsey & Company in Washington, D.C., where he advised senior leadership at Fortune 500 corporations and federal government agencies on strategic matters.

Mergers & Acquisitions

Mr. Khanani’s public and private mergers and acquisitions and strategic transaction practice has included representation of the following matters:

  • IXYS Corporation in its US$750 million sale to Littelfuse
  • Integrated Device Technology in its US$250 million acquisition of GigPeak
  • eResearchTechnology in its sale to Nordic Capital
  • Hightower in its strategic combination with VTS
  • Bridgepoint Advisors in its acquisition of Calypso TechnologyL2F in its sale to Middleby Corporation
Healthcare and Life Sciences
  • Landmark Health in its sale to General Atlantic
  • Relypsa, Inc. in its US$1.5 billion sale to Galenica AG
  • Encore Vision in its US$465 million acquisition by Novartis AG
  • Revolution Medicines in its acquisition of Warp Drive Bio
  • Alliance HealthCare Services in connection with the acquisition by Fujian Thai Hot Investment Co. of a majority of Alliance’s outstanding stock from Oaktree Capital and MTS Health Investors for US$102 million and a subsequent take-private transaction by Tahoe Investment Group Co. Ltd. for US$75 million
Venture Capital

Mr. Khanani regularly represents venture capital and growth equity firms in connection with private and public investments, acquisitions, and divestitures. Representative clients and matters have included:

  • KKR in its investments in Ajax Health, Blue Sprig Pediatrics, Trilogy MedWaste, and other healthcare portfolio companies
  • Andreessen Horowitz in the US$154 million Series C financing of TripActions and various other investments in early stage technology companies
  • Eclipse Ventures in its investments in Bright Machines, Owlet Baby Care, 6 River Systems, Instrumental, June, Mavrx, and other early stage technology companies
  • GreatPoint Ventures in its investments in Even Financial and other early stage technology companies
  • Questa Capital in its investments in Epix Therapeutics and Cortica
  • 8VC in various investments in early stage healthcare and technology companies
  • Formation8 in various investments in early stage technology companies
Emerging Companies and Public Company Representation

Mr. Khanani represents public and private companies in general corporate governance matters, equity investments, and strategic transactions. Representative clients and matters have included:

  • Bright Machines in its US$179 million Series A financing, joint venture with Flex, and other matters
  • Mellanox Technologies in its proxy contest defense against Starboard Value LP
  • Bebe in a strategic joint venture and sale of a minority interest
  • Soraa in its venture financings and strategic transactions
  • Calysta in its Series D financing, joint venture with Cargill, and other matters
  • Synack in its Series C financing
  • Alliance Healthcare Series in its strategic transactions
  • Memphis Meats in its Series A financing
  • Instrumental in its Series A financing
  • Avalon Healthcare Solutions in various matters
  • Relievant MedSystems in its Series E financing
  • Singulex in its Series B financing and strategic transactions
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.